The FDA approved Novo Nordisk's Awiqli (insulin icodec) on March 26, making it the first and only once-weekly basal insulin for adults with type 2 diabetes. The approval reduces insulin injections from seven per week to just one, a landmark shift in diabetes management that affects over 37 million Americans living with the condition.

Awiqli is the first new class of basal insulin to reach U.S. patients in more than two decades. The approval is based on the ONWARDS phase 3a programme comprising four randomized trials in approximately 2,680 adults. Administered via the FlexTouch pen on the same day each week, the drug showed comparable blood sugar control to daily insulins while dramatically improving treatment convenience.

Novo Nordisk expects to launch Awiqli in the U.S. in the second half of 2026. Analysts say the once-weekly format could significantly improve patient adherence, a persistent challenge in diabetes care where many patients skip or delay daily injections.